Hepatocellular Carcinoma (HCC)
Conditions
Keywords
urinary proteomics, Hepatocellular carcinoma recurrence after surgery
Brief summary
In this study, we explored and validated the predictive value of the longitudinal monitoring model of urinary proteomics for postoperative recurrence of hepatocellular carcinoma and the predictive value of minimal residual disease (MRD) status, verified whether it is earlier than the recurrence suggested by imaging tests, and initially explored its clinical feasibility in guiding the adjuvant treatment of hepatocellular carcinoma in the postoperative period, so as to provide a new idea for the strategy of early intervention in the postoperative period of hepatocellular carcinoma.
Interventions
DIAGNOSTIC_TESTUrine proteomics
Patients with hepatocellular carcinoma amenable to radical resection were included according to the inclusion exclusion criteria, and preoperative urine and postoperative urine from consecutive patients were collected at the marker time (before receiving postoperative adjuvant therapy after radical surgery for hepatocellular carcinoma) and at the longitudinal time (at the time point of 3 months after radical surgery), and the different samples were preprocessed, followed by mass spectrometry-based urinary proteomics to detect the differences in urinary proteins, and the data were recorded to compare the differences.
Sponsors
Zhujiang Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with hepatocellular carcinoma whose tumor stage at the time of initial diagnosis is consistent with BCLC staging 0/stage A/stage B, who can undergo radical surgical resection, and who have not received other antitumor therapy preoperatively.
Exclusion criteria
* Unable to provide specimens for testing such as urine proteomics; patients with a previous diagnosis of renal or urologic disease, two or more tumors at the same time; patients with non-primary foci of liver disease. Previously received anti-tumor therapy such as targeted immunotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year relapse-free survival | 2-year |
Countries
China
Outcome results
None listed